
- AptarGroup forecasts adjusted earnings per share (EPS) for Q2 2025 to be between $1.56 and $1.64, surpassing the previous estimate of $1.40.
- First quarter adjusted EPS decreased to $1.20 from $1.26 year-over-year but exceeded the estimate of $1.15.
- Net sales in Q1 were $887.3 million, a 3.1% decline from the previous year, missing the estimate of $904 million.
- Pharma net sales increased slightly by 0.5% year-over-year to $409.5 million, falling short of the $418.4 million estimate.
- Adjusted EBITDA for Q1 rose by 2.5% year-over-year to $183.3 million, surpassing the estimate of $180.4 million.
- The pharma sector achieved a 7.8% increase in adjusted EBITDA, reaching $142.5 million, higher than the $134.7 million estimate.
- The adjusted EBITDA margin was 20.7%, exceeding the estimated 19.9%.
- Beauty net sales fell 6.6% year-over-year to $305.7 million, which was below the estimate of $310.4 million.
- Closures net sales saw a 4.8% decrease from the previous year, reaching $172.1 million and missing the $184.4 million estimate.
- Beauty adjusted EBITDA dropped by 9.7% year-over-year to $37.1 million.
- Closures adjusted EBITDA increased slightly by 0.4% year-over-year to $27.3 million, below the $28.2 million estimate.
Aptargroup Inc on Smartkarma
Analysts on Smartkarma are bullish on Aptargroup Inc, with favorable coverage from reputable sources such as Upslope Capital Management and Baptista Research. In their Quarterly Investor Letter for 2025-Q1, Upslope highlighted the challenges faced in Q1 but noted a positive shift in global trade policies that benefited their portfolio. With a strong performance in April, the Fund is up 2% YTD, outperforming the S&P Midcap 400.
Similarly, Baptista Research‘s report on Aptargroup Inc emphasized the company’s active growth in materials science, driving their bullish sentiment. With a balanced performance across segments, Aptargroup saw a 2% core sales growth in the Pharma segment, fueled by demand for drug delivery systems. The company exceeded earnings expectations, with adjusted EPS of $1.52, reflecting solid operational performance and a favorable tax rate.
A look at Aptargroup Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a promising long-term outlook in the pipeline, Aptargroup Inc seems to be heading towards a bright future. Smart Scores highlight the company’s strengths in Growth and Momentum, with both scoring a high 4 out of 5. This indicates that Aptargroup Inc is on a strong growth trajectory and shows positive market momentum. Additionally, the company scores well in Resilience, with a score of 3, suggesting a level of stability in times of market volatility. However, there is room for improvement in Value and Dividend scores, both rated at 2, reflecting aspects where the company may seek to enhance its performance.
Aptargroup Inc, a global player in designing, manufacturing, and marketing pumps, dispensing closures, and aerosol valves, caters to a wide range of industries including fragrance/cosmetics, personal care, pharmaceutical, household/industrial, and food products. With its wide international presence, the company is well-positioned to capitalize on its strengths in growth and market momentum. As Aptargroup Inc continues to focus on enhancing its value and dividend offerings, these efforts could further solidify its standing in the market and attract more investors seeking stable and growing opportunities.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars